Matthew Rettig, MD
Institutional Affiliation
Education
Fellowship
Internship
Degree
Residency
Board Certifications
Contact Information
Phone
Scientific Interests
Dr. Matthew Rettig focuses on the management of genitourinary malignancies, with a clinical emphasis on advanced prostate cancer and a research emphasis on identifying biochemical targets for therapeutic translation in castration-resistant prostate cancer and clear cell renal cell carcinoma.
Highlighted Publications
An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther. 2007; 6(1): 61-9.
An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol. 2005; 25(17): 7546-56.
Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004; 64(2): 335-40.
An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003; 9(12): 4537-45.
An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003; 22(22): 3371-85.
